The in-vitro activity of levofloxacin was compared with ofloxacin and D-ofloxacin against 130 isolates of Staphylococcus aureus and 117 isolates of coagulase-negative staphylococci, using the agar dilution method. In general, levofloxacin was equally active or up to fourfold more active than ofloxacin against all staphylococci, including 61 methicillin-resistant S. aureus. In contrast, D-ofloxacin showed little activity against all isolates tested.
Introduction
Ofloxacin is characterized chemically by a tricyclic structure with a methyl group at the C-3 position in the oxazine ring. This provides an asymetric centre at this position, and ofloxacin is currently formulated as a racemic mixture of Sand R isomers. Levofloxacin is the 5-( -)-isomer and is the more potent of the two optically active isomers of ofloxacin (Fu et al., 1992; Davis & Bryson, 1994) . This is the first report of the in-vitro antistaphylococcal activity of ofloxacin isomers, in which a large number of different species, including methicillin-resistant isolates were tested and multiple isolates of the same strain were excluded by genomic typing. In our study, levofloxacin was at least as active as ofloxacin against all staphylococci, including 61 methicillin-resistant Staphylococcus aureus. In contrast, D-ofloxacin showed little activity against all isolates tested.
Materials and methods
A total of 247 staphylococci freshly isolated from clinical material was tested. These isolates came from several university and community hospitals in Germany. Only one isolate per patient was tested. Multiple isolates of the same strain were initially excluded by antibiograms and phenotypic characterization. In addition, we used several other criteria to avoid including multiple isolates of the same strain. Firstly, isolates were collected from different geographic locations (both within the hospitals and from different hospitals), which would reduce the chance of obtaining a single clone.
•Tel: +49-251-835360; Fax: +49-251-835350. Staphylococcus cohnii). The MICs were determined on Mueller-Hinton agar (Difco, Augsburg, Germany), using the agar dilution technique with an inoculum of 10 s cfu. Isolates were confirmed to be methicillin-resistant by supplementation of the agar with 2% NaCl (read after incubation for 48 h at 30°C). The following antimicrobial agents were used; ofloxacin and D-ofloxacin (both supplied by Hoechst AG, Frankfurt, Germany) and levofloxacin (Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan). With the exception of D-ofloxacin, the antibiotics were tested in 13 different concentrations ranging from 0.031 to 128 mg/L. D-ofloxacin was tested in 12 different concentrations ranging from 0.031 to 64 mg/L. The results were read after 18 h incubation at 36°C. The following reference strains were included as controls: 5. aureus ATCC 25923, ATCC 29213; Enter-ococcus faecalis ATCC 29212; Escherichia coli ATCC 25922, ATCC 35218; Pseudomonas aeruginosa ATCC 27853. Additionally, sterility and growth controls were always performed.
Results
The MIC ranges, the MICJOS and the MIG»s for the 130 isolates of S. aureus are shown in Table I . For PSSA and MSSA, levofloxacin was slightly more active than ofloxacin as determined by MIC»s (0.25 mg/L) and equally active as determined by MIQoS (0.5 mg/L) of the isolates. Against methicillin-resistant isolates, levofloxacin was again more active than ofloxacin (MIC™, 16 mg/L). However, it showed less activity against methicillin-resistant isolates compared with PSSA and MSSA. D-ofloxacin had poor activity against all S. aureus isolates, especially against MRSA (MICw > 64 mg/L). The ranges of MICs, the MICJOS and the MIC«s for the 117 isolates of coagulase-negative staphylococci tested are shown in Table II . Against CNS levofloxacin was again the most active antimicrobial agent tested. For both MSSE and MSSH, levofloxacin was two-fold more active than ofloxacin, with MIC90S of 0.25 and 1 mg/L, respectively. Single isolates with elevated levofloxacin and ofloxacin MICs were observed (up to 32 mg/L and 128 mg/L, respectively). Against MRSE and MRSH, the quinolones tested were less active compared with the methicillin-susceptible strains, with levofloxacin being marginally more active than ofloxacin. Overall, the in-vitro activity against 5. epidermidis was higher than the activity against S. haemolyticus. The in-vitro activity against other coagulase-negative staphylococci tested, belonging to novoviocinsusceptible and novobiocin-resistant species, was comparable to the activity against MSSH. Again, D-ofloxacin showed little activity against all CNS tested, including the methicillin-susceptible isolates.
Quality control of all MIC determinations was performed using the reference strains mentioned above. 
Discussion
During the past decade, there has been continued interest in improving the antibacterial activities of fluorinated quinolones. Most of these agents, including ofloxacin, norfloxacin, ciprofloxacin and fleroxacin have broader antimicrobial spectra and improved bioavailabilities in comparison with those of naladixic acid (Wolfson & Hooper, 1985) . However, the emergence of resistance in staphylococci has become problematic: methicillin-resistant strains of S. aureus and coagulase-negative staphylococci are increasingly causing serious clinical problems in a variety of nosocomial infections (Kloos & Bannerman, 1994; Voss et al., 1994) . Additionally, ciprofloxacin-resistant staphylococci have been reported with increasing frequency (Blumberg et al., 1991) . Thus, alternatives to these antimicrobials are urgently needed in the prospect of multiple-resistant strains. In this context, we tested the in-vitro antistaphylococcal activity of ofloxacin isomers. Levofloxacin was equally active or up to fourfold more active than ofloxacin against S. aureus. A similar pattern was seen for all other Staphylococcus spp. studied. However, as for S. aureus, the in-vitro activity of the three fluoroquinolones tested against coagulase-negative staphylococci was dependent on the methicillin-resistant phenotype of the isolates. D-ofloxacin exhibited no antistaphylococcal activity, as this agent revealed poor activity against all isolates tested. The antimicrobial susceptibilities of our staphylococci were generally in agreement with those reported by other investigators (Dholakia el al., 1994; Yamane et al., 1994) , showing that levofloxacin was at least as active as ofloxacin against methicillin-susceptible and -resistant staphylococci, even though we tested a larger number of methicillin-resistant isolates and excluded multiple isolates of the same strain. However, our results for methicillin-resistant staphylococci differed from those in previous studies (Une et al., 1988; Fu et al., 1992) in which it was reported that levofloxacin was active against methicillin-resistant staphylococci at concentrations almost equal to those obtained against methicillin-susceptible strains. In contrast, we found that methicillin-resistant staphylococci, especially S. aureus, S. epidermidis, and S. haemolyticus, were highly levofloxacin-resistant with MIC90S of 16 mg/L. In contrast to previous studies (Foleno, Lafredo & Fu, 1993; Dholakia et al., 1994) , we tested a larger number of different species of coagulase-negative staphylococci and included methicillin-susceptible and -resistant isolates.
Overall, levofloxacin had superior in-vitro antistaphylococcal activity than the other agents tested, whereas many staphylococci were resistant to D-ofloxacin.
